Sarepta Therapeutics | SRPT - Operating Expenses


Sarepta Therapeutics reported $462.23M in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 242.88M 10.68M Sep/2025
Agios Pharmaceuticals USD 141.54M 11.8M Dec/2025
Alnylam Pharmaceuticals USD 965.32M 84.27M Dec/2025
Amgen USD 5.9B 773M Dec/2025
BioCryst Pharmaceuticals USD -387.89M 33.7M Sep/2025
Biogen USD 1.88B 81.4M Sep/2025
BioMarin Pharmaceutical USD 807.82M 259.3M Sep/2025
Capricor Therapeutics USD 24.98M 6.15M Mar/2025
Daiichi Sankyo JPY 468.57B 15.34B Dec/2025
Eli Lilly USD 10.31B 1.09B Dec/2025
Esperion Therapeutics USD 67.66M 3.6M Sep/2024
Gilead Sciences USD 4.96B 707M Dec/2025
Incyte USD 1.12B 3.53B Dec/2025
Insmed USD 513.55M 109.86M Dec/2025
Ionis Pharmaceuticals USD 316.9M 4.69M Sep/2025
Moderna USD 1.54B 259M Dec/2025
Nektar Therapeutics USD 85.09M 109.3M Sep/2025
Neurocrine Biosciences USD 577.6M 22M Dec/2025
Novavax USD 218.53M 34.86M Sep/2024
Pfizer USD 12.91B 79.89B Dec/2025
PTC Therapeutics USD 246.3M 38.78M Dec/2025
Regeneron Pharmaceuticals USD 2.99B 27.97B Dec/2025
Roche Holding CHF 21.01B 10.84B Dec/2025
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Sanofi EUR 10.51B 1.21B Dec/2025
Sarepta Therapeutics USD 462.23M 33.28M Sep/2025
Tectonic Therapeutic USD 21.89M 440K Sep/2025
Ultragenyx Pharmaceutical USD 321M 9.82M Dec/2025
Vertex Pharmaceuticals USD 1.93B 89.1M Dec/2025